USPTO Examiner MONTANARI DAVID A - Art Unit 1632

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
16958630ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOFJanuary 2021March 2025Allow5711YesNo
17253956ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MUSCLE SPECIFIC MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHYDecember 2020March 2025Allow5121YesNo
17125930COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTIONDecember 2020July 2023Allow3110NoNo
17124667A method of cell therapyDecember 2020January 2025Allow4911YesNo
17122562HAPLOID HUMAN EMBRYONIC STEM CELL LINES AND SOMATIC CELL LINES AND METHODS OF MAKING THE SAMEDecember 2020May 2024Allow4111NoNo
17251360CROSS-LINKABLE CELLULOSE AS 3D PRINTING MATERIALDecember 2020May 2024Abandon4101NoNo
17101785ANTI-CD19 CAR-T CELLNovember 2020December 2024Allow4911YesNo
16953473METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEMNovember 2020February 2024Allow3911NoNo
16953068MODIFIED GAMMA DELTA T CELLS AND USES THEREOFNovember 2020May 2024Abandon4111NoNo
16950244USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLSNovember 2020January 2024Allow3811NoNo
17099421METHODS AND COMPOSITIONS FOR TREATMENT OF OCULAR DISORDERS AND BLINDING DISEASESNovember 2020May 2024Allow4211YesNo
17097815RNA TRANSCRIPTION VECTOR AND USES THEREOFNovember 2020July 2024Abandon5421NoNo
17089474CANCER IMMUNOTHERAPY USING CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORSNovember 2020August 2021Allow910YesNo
17077782CHIMERIC ANTIGEN RECEPTOROctober 2020July 2023Abandon3310NoNo
17077545TRANSGENIC ANIMALS AND METHODS OF USEOctober 2020May 2024Allow4311YesNo
17071574NON-INVASIVE, IN VITRO FUNCTIONAL TISSUE ASSAY SYSTEMSOctober 2020June 2023Allow3210NoNo
17031367NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN LOCUSSeptember 2020June 2025Allow5631YesNo
17030057ENHANCED IMMUNOGLOBULIN DIVERSITYSeptember 2020September 2023Allow3611YesNo
17021240GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIESSeptember 2020July 2021Allow1011NoNo
17021234GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIESSeptember 2020July 2021Allow1011NoNo
17021238GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIESSeptember 2020December 2023Abandon3911NoNo
17021242GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIESSeptember 2020December 2023Abandon3911NoNo
17015947METHOD FOR INDUCING A TOLEROGENIC IMMUNE RESPONSESeptember 2020June 2024Allow4621YesNo
16979458Improved Oncolytic ReovirusSeptember 2020March 2025Allow5421YesNo
17013830MICROENVIRONMENTS FOR SELF-ASSEMBLY OF ISLET ORGANOIDS FROM STEM CELLS DIFFERENTIATIONSeptember 2020January 2024Allow4011NoNo
17013135UNIVERSAL DONOR CELLSSeptember 2020May 2021Allow911YesNo
17012651GENERATING HUMAN PODOCYTE CELLSSeptember 2020February 2024Allow4111NoNo
16977506CLOSED-ENDED DNA (CEDNA) VECTORS FOR INSERTION OF TRANSGENES AT GENOMIC SAFE HARBORS (GSH) IN HUMANS AND MURINE GENOMESSeptember 2020June 2025Abandon5821NoNo
17009279PRODUCTION AND USE OF RED BLOOD CELLSSeptember 2020December 2023Abandon3920NoNo
17004698POPULATION CONTROL USING ENGINEERED TRANSLOCATIONSAugust 2020September 2024Allow4921YesNo
17000140GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOFAugust 2020May 2023Allow3310NoNo
16997184GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIESAugust 2020November 2021Allow1521YesNo
16995372TRANSGENIC SILKWORMS EXPRESSING HAGFISH THREAD KERATINAugust 2020March 2024Allow4321YesNo
16993160METHOD FOR GENERATING IMMUNE CELLS RESISTANT TO ARGININE AND/OR TRYPTOPHAN DEPLETED MICROENVIRONMENTAugust 2020August 2024Allow4821YesNo
16968317PANCREATIC CELLS FOR TREATING DIABETES AND METHODS OF GENERATING THE SAMEAugust 2020June 2022Allow2321YesYes
16934848SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOFJuly 2020April 2021Allow921YesNo
16934412SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAMEJuly 2020July 2021Allow1211YesNo
16934885SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOFJuly 2020April 2021Allow921YesNo
16934764SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOFJuly 2020April 2021Allow911NoNo
16962973Method for Differentiation of Human Pluripotent Stem Cell Lines in Suspension CultureJuly 2020April 2024Allow4511YesNo
16920286INDIVIDUALIZED VACCINES FOR CANCERJuly 2020October 2021Allow1510YesNo
16912084BACULOVIRUS EXPRESSION SYSTEMJune 2020May 2023Allow3441YesNo
16892106METHODS FOR MAKING INSULIN IN VIVOJune 2020January 2023Abandon3210NoNo
16767527CELL CULTURE CONTAINER CAPABLE OF LONG-TERM CULTURE AND METHOD FOR MANUFACTURING SAMEMay 2020April 2024Abandon4601NoNo
16858435AAV/XBP1S-HA VIRUS, GENE THERAPY METHOD AND USE THEREOF IN THE OPTIMISATION AND IMPROVEMENT OF LEARNING, MEMORY AND COGNITIVE CAPACITIESApril 2020May 2024Abandon4821YesNo
16849847TRANSGENIC MAMMALS AND METHODS OF USE THEREOFApril 2020March 2024Allow4711YesNo
16844657PROTECTED GUIDE RNAS (PGRNAS)April 2020November 2022Allow3110YesNo
16844548OPTIMIZED CRISPR-CAS DOUBLE NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATIONApril 2020November 2022Allow3110NoNo
16817413GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSEMarch 2020October 2023Allow4330YesNo
16793896METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEMFebruary 2020November 2020Allow910NoNo
16793918METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEMFebruary 2020January 2022Allow2310NoNo
16794115MITOCHONDRIAL TRANSPLANTATION TO ALTER ENERGY METABOLISMFebruary 2020December 2022Abandon3411NoNo
16790246GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIESFebruary 2020August 2020Allow610NoNo
16790263GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIESFebruary 2020September 2020Allow710NoNo
16745873CHIMERIC CAPSIDSJanuary 2020August 2024Allow5521YesNo
16735683COMPOUNDS, COMPOSITIONS, METHODS, AND KITS RELATING TO TELOMERE EXTENSIONJanuary 2020July 2023Allow4211YesNo
16735684COMPOUNDS, COMPOSITIONS, METHODS, AND KITS RELATING TO TELOMERE EXTENSIONJanuary 2020February 2024Allow5011NoNo
16729852HUMANIZED LIGHT CHAIN MICEDecember 2019November 2022Allow3410NoNo
16729798HUMANIZED LIGHT CHAIN MICEDecember 2019November 2022Allow3510NoNo
16717923METHODS OF MAKING HUMAN PRIMITIVE ECTODERM CELLSDecember 2019February 2023Allow3811NoNo
16708180DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCERDecember 2019September 2024Allow5830NoNo
16707223GENE-THERAPY VECTORS FOR TREATING CARDIOMYOPATHYDecember 2019May 2023Allow4111YesNo
16694040EFFICIENT INDUCTION OF DEFINITIVE ENDODERM FROM PLURIPOTENT STEM CELLSNovember 2019December 2023Abandon4930YesNo
16614170A TRANSGENIC INVERTEBRATE MODEL FOR ALZHEIMER'S DISEASE AND USE THEREOFNovember 2019October 2023Allow4721YesNo
16682541Differentiation of Pluripotent Stem Cells to Form Renal OrganoidsNovember 2019July 2024Allow5621YesNo
16679100METHODS OF PRODUCING PANCREATIC HORMONESNovember 2019June 2023Allow4311YesNo
16611781ACCELERATION OF STEM CELL DIFFERENTIATIONNovember 2019February 2023Allow3911YesNo
16676196DNA VACCINES AND METHODS FOR THE PREVENTION OF TRANSPLANTATION REJECTIONNovember 2019August 2023Abandon4511NoNo
16665892COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTIONOctober 2019October 2020Allow1110NoNo
16657428CD34+,CD45- PLACENTAL STEM CELL-ENRICHED CELL POPULATIONSOctober 2019October 2023Abandon4820NoNo
16657202TRIPLOID SHELLFISHOctober 2019January 2024Abandon5131YesNo
16606120ANTIGEN-SPECIFIC IMMUNE EFFECTOR CELLSOctober 2019July 2024Allow5731YesNo
16599620METHODS AND SYSTEMS FOR CONVERTING PRECURSOR CELLS INTO INTESTINAL TISSUES THROUGH DIRECTED DIFFERENTIATIONOctober 2019August 2024Allow5830YesNo
16598920DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLSOctober 2019March 2023Allow4120NoNo
16586786DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLSSeptember 2019July 2022Allow3410YesNo
16498831ADDITION OF NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND CLEARANCE OF HOST CELL NUCLEIC ACIDSSeptember 2019November 2023Abandon4920NoNo
16582279PANCREATIC ENDOCRINE CELLS AND METHODS THEREOFSeptember 2019September 2023Allow4830YesNo
16583135PDX1 POSITIVE FOREGUT ENDODERM CELLS AND METHODS OF PRODUCTIONSeptember 2019December 2022Allow3810NoNo
16579396Alphavirus Replicon Particles Expressing TRP2September 2019January 2025Abandon6041NoYes
16573985SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOFSeptember 2019December 2023Abandon5030YesNo
16493877INDUCED TOTIPOTENT STEM CELLS AND METHODS FOR MAKING AND USING THE SAMESeptember 2019September 2022Abandon3601NoNo
16568116TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORSSeptember 2019January 2021Allow1611YesNo
16490394PANCREATIC PROGENITOR CELL PRODUCTION METHODAugust 2019November 2022Abandon3801NoNo
16544993MAINTENANCE CULTURE OF INDUCED PLURIPOTENT STEM CELL-DERIVED INTESTINAL STEM CELLSAugust 2019March 2023Allow4311YesNo
16486360MAMMALIAN CELLS FOR PRODUCING ADENO-ASSOCIATED VIRUSESAugust 2019June 2023Allow4621YesNo
16539401METHODS FOR LOWERING BLOOD GLUCOSEAugust 2019February 2022Allow3010NoNo
16530777Generation of Human Spinal Cord Neural Stem CellsAugust 2019May 2023Allow4621YesNo
16528803METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOFAugust 2019February 2022Allow3111NoNo
16481418ENDODERMAL CELL POPULATION, AND METHOD FOR PRODUCING CELL POPULATION OF ANY OF THREE GERM LAYERS FROM PLURIPOTENT CELLJuly 2019May 2023Allow4621NoNo
16480025MEDIA AND METHODS FOR ENHANCING THE SURVIVAL AND PROLIFERATION OF STEM CELLSJuly 2019February 2023Allow4331YesNo
16478307Maintenance and Expansion of Pancreatic Progenitor CellsJuly 2019May 2023Abandon4620NoNo
16458740CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCERJuly 2019January 2022Allow3111YesNo
16445124METHODS OF MAKING AND USING PDX1-POSITIVE PANCREATIC ENDODERM CELLSJune 2019October 2021Allow2811NoNo
16436545GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPaJune 2019February 2021Allow2011YesNo
16435428DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO SINGLE HORMONAL INSULIN POSITIVE CELLSJune 2019February 2022Allow3211NoNo
16432026CERAMIDASE AND CELL DIFFERENTIATIONJune 2019July 2023Abandon4921NoNo
16429978LATE-ONSET ALZHEIMER'S DISEASE ANIMAL MODEL AND USES THEREOFJune 2019January 2024Allow5521NoNo
16418893METHODS AND SYSTEMS FOR GUIDE RNA DESIGN AND USEMay 2019January 2022Allow3231YesNo
16416580A METHOD TO DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO FUNCTIONAL HEART MUSCLEMay 2019March 2023Abandon4611NoNo
16415309CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCERMay 2019August 2021Allow2711YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MONTANARI, DAVID A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
13
Examiner Affirmed
7
(53.8%)
Examiner Reversed
6
(46.2%)
Reversal Percentile
68.2%
Higher than average

What This Means

With a 46.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
118
Allowed After Appeal Filing
37
(31.4%)
Not Allowed After Appeal Filing
81
(68.6%)
Filing Benefit Percentile
49.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 31.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MONTANARI, DAVID A - Prosecution Strategy Guide

Executive Summary

Examiner MONTANARI, DAVID A works in Art Unit 1632 and has examined 782 patent applications in our dataset. With an allowance rate of 58.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner MONTANARI, DAVID A's allowance rate of 58.2% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MONTANARI, DAVID A receive 2.43 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MONTANARI, DAVID A is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +52.8% benefit to allowance rate for applications examined by MONTANARI, DAVID A. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.4% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.2% of cases where such amendments are filed. This entry rate is in the 57% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 46.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 84.5% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 81.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 79.5% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.1% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 56% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.